A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

Nature Biotechnology

Volumn 17, Issue 3, 1999, Pages 276-281

  Huls, Gerwin A ^a   Heijnen, Ingmar A F M ^a   Cuomo, Maria E ^a   Koningsberger, Jacob C ^a   Wiegman, Luus ^a   Boel, Edwin ^a   Van Der Vuurst De Vries, Anne Reneé ^a   Loyson, Sabine A J ^a   Helfrich, Wijnand ^b   Van Berge Henegouwen, Gerard P ^a   Van Meijer, Marja ^a   De Kruif, John ^a   Logtenberg, Ton ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Ep CAM; Immunotherapy; Phage display; Recombinant antibodies; Single chain Fv

Indexed keywords

CANCER ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CYTOTOXICITY; GENE ISOLATION; PHAGE DISPLAY; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BACTERIOPHAGES; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL COUNT; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; GENE LIBRARY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR BIOLOGY; NEUTROPHILS; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033058420     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/7023     Document Type: Article

References (45)

1. Shawler, D.L., Bartholomew, R.M., Smith, L.M. & Dillman, R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135, 1530-1535 (1985).
2. Miller, R.A., Oseroff, A.R., Stratte, P.T. & Levy, R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62, 988-995 (1983).
3. Hakimi, J. et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J. Immunol. 147, 1352-1359 (1991).
4. Stephens, S. et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 85, 668-674 (1995).
5. Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 333, 323-327 (1988).
6. Junghans, R.P. et al. Anti-Tac-H, a humanized antibody to the interteukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50, 1495-1502 (1990).
7. Vaughan, T.J., Osbourn, J.K. & Tempest, P.R. Human antibodies by design. Nat. Biotechnol. 16, 535-539 (1998).
8. Khazaeli, M.B. et al. Pharmacokinetics and immune response of 1311-chimeric mouse/human B72.3 (human gamma4) monoclonal antibody in humans. Cancer Res. 51, 5461-5466 (1989).
9. Elliot, M.J. et al. Repeated therapy with monoclonal antibody to tumor necrosis factor alfa (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-1127 (1994).
10. Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525 (1986).
11. Foote, J. & Winter, G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224, 487-499 (1992).
12. McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1998).
13. Pegram, M.D. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 Her2/neu monoclonal antibody plus cisplatin in patients with Her2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659-2671 (1998).
14. Vincenti, F. et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N. Engl. J. Med. 338, 161-165 (1998).
15. Bruggeman, M. & Neuberger, M.S. Strategies for expressing human antibody repertoires in transgenic mice. Immunol. Today 17, 391-397 (1996).
16. Mendez, M.J. et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146-156 (1997).
17. Winter G., Griffiths, A.D., Hawkins, R.E. & Hoogenboom, H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455 (1994).
18. Burton, D.R. & Barbas III, C.F. Human antibodies from combinatorial libraries. Adv. Immunol. 57, 191-280 (1994).
19. De Kruif, J., Terstappen, L., Boel, E. & Logtenberg, T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sci. USA 92, 3938-3942 (1995).
20. Riethmuller, G. et al. 1994. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes = C colorectal carcinoma. Lancet 343, 1177-1183 (1994).
21. De Kruif, J., Boel, E.Z. & Logtenberg, T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248, 97-105 (1995).
22. Gottlinger, H.G., Funke, I., Johnson, J., Gokel, J.M. & Riethmuller, G. The epithelial cell surface antigen CO17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int. J. Cancer 38, 47-53 (1986).
23. Momberg, F., Moldenhauer, G., Hammerling, G.J. & Moller, P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 47, 2883-2891 (1987)
24. Thampoe, I.J., Ng, J.S.C. & Lloyd, K.O. Biochemical analysis of a human epithelial surface antigen: differential cell expression and processing. Arch. Biochem. Biophys. 267, 342-352 (1988).
25. Simon, B. et al. Epithelial glycoprotein is a member of a family of epithelial surface antigens homologous to nidogen, a matrix adhesion protein. Proc. Natl. Acad. Sci. USA 87, 2755-2759 (1990).
26. Litvinov, S.V., Velders, M.P., Bakker, H.A.M., Fleuren, G.J. & Warnaar, S.O. EpCAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol. 125, 437-446 (1994).
27. Steplewski, Z. et al. Biological activity of human-mouse IgG1, IgG2, IgG3 and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. USA 85, 4852-4856 (1988).
28. Pak, K.Y. et al. 1991. Evaluation of the 323/A3 monoclonal antibody and the use of technetium-99m-labeled 323/A3 Fab' for the detection of panadenocarcinoma. Int. J. Rad. Appl. Instrum. 18, 483-497 (1991).
29. Velders, M.P. et al. The role of antibody affinity in tumor immunotherapy evaluated in in-vivo models for minimal residual disease. J. Immunother. 19, 245-256 (1996).
30. Heijnen, I.A.F.M. & van de Winkel, J.G.J. Human IgG Fc receptors. Int. Rev. Immunol. 16, 29-56 (1997).
31. Valerius, T. et al. Involvement of the high affinity receptor for IgG (FcgammaRI:CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 82, 931-939 (1993).
32. Naramura, M., Gillies, S.D., Mendelsohn, J., Reisfeld, R.A. & Mueller, B.M. Therapeutic potential of chimeric and murine anti-EGF receptor antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. 37, 343-349 (1993).
33. Nishimura, Y. et al. Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. Cancer Res. 47, 999-1005 (1987).
34. Liu, A.Y. et al. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc. Natl. Acad. Sci. USA. 84, 3439-3443 (1987).
35. Takahashi, H., Nakada, T., Nakaki, M. & Wands, J.R. Inhibition of hepatic metastases of human colon cancer in nude mice by a chimeric SF-25 monoclonal antibody. Gastroenterology. 108, 172-182 (1995).
36. Walker, M.R., Lund, J., Thompson, K.M. & Jefferis, R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem. J. 259, 347-353 (1989).
37. LoBuglio, A.F. et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA 86, 4220-4224 (1989).
38. Balzar, M. et al. Cytoplasmic tail regulates the intercellular adhesion function of the epithelial cell adhesion molecule. Mol. Cell. Biol. 18, 4833-4843 (1998).
39. De Leij, L., Helfrich, W., Stein, R. & Mattes, M.J. SCLC Cluster 2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int. J. Cancer suppl. 8, 60-63 (1994).
40. Meerman, H.J. & Georgiou, G. Construction and characterization of a set of E. coli strains deficient in all known loci affecting the proteolytic stability of secreted recombinant proteins. Bio/Technology 12, 1107-1109 (1994).
41. De Kruif, J., Storm, G., van Bloois, L. & Logtenberg, T. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett. 199, 232-236 (1996).
42. Hale, J.E. Irreversible, oriented immobilization of antibodies to cobalt-iminodiacetate resin for use as immunoaffinity media. Anal. Biochem. 231, 46-49 (1995).
43. Lankhof, H. PhD thesis. University of Utrecht. The Netherlands (1996).
44. Karlsson, R., Michaelson, A. & Mattson, L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods. 198, 129-137 (1991).
45. Van Strijp, J.A.G., van Kessel, K.P.M., van der Tol, M.E. & Verhoef, J. Complement-mediated phagocytosis of herpes simplex virus by human granulocytes: binding or ingestion. J. Clin. Invest. 84, 107-112 (1989).